Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

9,977 public trials 2,028 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

A Safety Study in Patients With Chronic Lymphocytic Leukemia

NCT00283101

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +14 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • University of Miami, Sylvester Comprehensive Cancer Center Miami, Florida, United States
  • Weill Medical College/Cornell University New York, United States
  • Fred Hutchinson Cancer Research Center Seattle, Washington, United States
View Trial Details
Completed

A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma

NCT01015911

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +20 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • City of Hope National Medical Center Duarte, California, United States
  • UCLA Medical Center / University of California at Los Angeles Los Angeles, California, United States
  • Karmanos Cancer Institute / Wayne State University Detroit, Michigan, United States
View Trial Details
Completed

Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies

NCT00430846

Conditions
Disease, Hodgkin, Hematologic Diseases, Hemic and Lymphatic Diseases, +11 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Washington University St Louis, Missouri, United States
  • Weill Cornell Medical College New York, United States
  • University of Texas/MD Anderson Cancer Center Houston, Texas, United States
View Trial Details
Completed

A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma

NCT01060904

Conditions
Disease, Hodgkin, Hematologic Diseases, Hemic and Lymphatic Diseases, +8 more
Locations
  • Mayo Clinic Rochester, Minnesota, United States
  • UNC Lineberger Comprehensive Cancer Center / University of North Carolina Chapel Hill, North Carolina, United States
  • MD Anderson Cancer Center / University of Texas Houston, Texas, United States
  • British Columbia Cancer Agency - Vancouver Centre Vancouver, British Columbia, Canada
View Trial Details
Completed

Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma

NCT00079755

Conditions
Anaplastic Large-Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • University of Alabama, Birmingham Birmingham, Alabama, United States
  • University of Califorinia at Los Angeles Los Angeles, California, United States
  • Georgetown University Washington D.C., District of Columbia, United States
  • University of Miami Miami, Florida, United States
View all 18 locations
View Trial Details
Completed

Cardiac Safety Study of Brentuximab Vedotin (SGN-35)

NCT01026233

Conditions
Disease, Hodgkin, Hematologic Diseases, Hemic and Lymphatic Diseases, +11 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • City of Hope National Medical Center Duarte, California, United States
  • Stanford Cancer Center Stanford, California, United States
  • University of Miami Hospital and Clinics, Miller School of Medicine Miami, Florida, United States
View Trial Details
Completed

Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation

NCT01767714

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations
  • Investigational Site Number 156017 Beijing, China
  • Investigational Site Number 156001 Beijing, China
  • Investigational Site Number 156005 Beijing, China
  • Investigational Site Number 156002 Beijing, China
View all 16 locations
View Trial Details
Completed

A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCT

NCT00460421

Conditions
Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations
  • Arizona Cancer Center Tucson, Arizona, United States
  • Loma Linda University Loma Linda, California, United States
  • Children´s Hospital Los Angeles, California, United States
  • Regents of University of California Los Angeles, California, United States
View Trial Details

Related conditions